Top 5 Papers
#1
Source: FDA approval (Freenome / Abbott) + Journal of the National Cancer Institute | Authors: Shaukat A, Levin TR and Freenome Holdings (PREEMPT CRC, NCT04369053) | Published: Approval July 27, 2026; JNCI analysis published January 9, 2026
Score: 11/20 — Base 8 (FDA regulatory action) + a new FDA-approved screening modality entering the Medicare coverage pathway and commercial distribution through Abbott (+2) + biomarker-guided / precision (+1) = 11. The +2 is deliberately not the +3 reserved for a new standard of care, because the 2026 ACS guideline in this same edition places blood-based tests behind stool-based and endoscopic options rather than alongside them.
The FDA approved SimpleScreen CRC on July 27, 2026, a cell-free DNA methylation blood test for average-risk adults 45 and older, with Abbott commercialising it in the US. The validation behind it is genuinely strong: PREEMPT CRC enrolled more than 48,000 asymptomatic average-risk adults aged 45–85 across over 200 sites, all of whom were scheduled for screening colonoscopy — the reference standard applied to everyone, which is the design a screening test should have to survive. The label numbers come from a prespecified post-stratification analysis published in JNCI in January 2026, and reading it carefully matters. Adjusting the cohort to the US Census age and sex distribution raised CRC sensitivity from an observed 79.2% (95% CI 68.4–86.9) to 81.1% (71.3–88.1), raised advanced precancerous lesion sensitivity from 12.5% (11.3–13.8) to 13.7% (12.4–15.0), and lowered specificity for advanced neoplasia from 91.5% (91.2–91.9) to 90.4% (90.0–90.7). The headline 81.1% is therefore an adjusted figure, not the raw observed one, and the adjustment moved specificity the other way. The number that should shape how you counsel patients is 13.7%: this test detects roughly four in five established cancers and roughly one in seven advanced precancerous lesions. It is a cancer-detection test, not a cancer-prevention test. That distinction is the entire subject of this edition — and it is the axis on which yesterday's DENEB assay, which claimed 81% sensitivity for advanced adenomas in a case-control design, is asking to be judged.
Post angle: The approved test finds 4 in 5 cancers and 1 in 7 advanced precancers. Both numbers are real, and only one of them is usually quoted. Worth knowing that 81.1% is census-adjusted; observed was 79.2%. #CRC #GIOnc #Screening #LiquidBiopsy
#2
Source: CA: A Cancer Journal for Clinicians | Authors: Wolf AMD, Smith RA and the ACS Guideline Development Group | Published: 2026 (volume 76, issue 3)
Score: 10/20 — Base 7 (major screening guideline update, scored with the NCCN guideline tier) + updated standard-of-care guidance that reorders the recommended screening menu (+3) = 10. Scores below the lead only because the FDA approval is the news event this edition is organised around; on evidence-shaping weight the two are close.
The American Cancer Society reaffirmed screening from age 45 through 75 for average-risk adults with a life expectancy over 10 years, and then did something more consequential: it graded the new molecular tests against each other. The next-generation multitarget stool DNA test and the multitarget stool RNA test both showed high sensitivity for colorectal cancer and moderate sensitivity for advanced precancerous lesions, and join annual high-sensitivity FIT and gFOBT as preferred stool-based options at three-year intervals. Blood-based tests did not. In the guideline's own words, they "demonstrated lower sensitivity for both advanced precancerous lesions and stage I cancers, with modeling studies predicting less effectiveness in reducing CRC incidence and mortality," and "at this time, blood-based tests should be recommended only to individuals who decline or do not complete preferred screening tests." The ACS also restates the point that makes any of this work: a positive result on any non-colonoscopy test requires colonoscopy, preferably within six months, or the screening episode is not complete. Read alongside the SimpleScreen approval, this is the field drawing a careful line — a blood test is a way to reach the unscreened, not a substitute for the tests that prevent cancer.
Post angle: The most useful sentence in colorectal screening this year is in an ACS guideline, not a trial: blood-based tests should be offered only to people who decline or don't complete a preferred test. Access tool, not equivalent. #CRC #GIOnc #Screening
#3
Source: CMS National Coverage Determination 210.3 (announced via Geneoscopy) | Authors: Centers for Medicare & Medicaid Services; Geneoscopy, Inc. | Published: CMS final coverage memorandum June 8, 2026
Score: 9/20 — Base 8 (major payer/regulatory action) + materially expanded access to a guideline-preferred modality (+1) = 9. No further clinical-impact bonus: this is a coverage decision on an already-approved test, not new performance data.
CMS updated the national coverage determination for colorectal cancer screening to cover ColoSense, a stool-RNA test, making it available to Medicare and Medicare Advantage beneficiaries — roughly 65 million people — at three-year intervals for average-risk adults 45 and older. The timing is the interesting part. Within about two weeks of this decision, the ACS named the multitarget stool RNA test a preferred screening option, and the reported performance shows why the two moved together: 93% sensitivity for colorectal cancer and 45% sensitivity for advanced adenomas in average-risk patients. That 45% is the number to hold next to the blood tests in this edition. It is not colonoscopy, and it is not DENEB's claimed 81%, but it is more than three times the 13.7% advanced-precancer sensitivity on the newly approved blood test — achieved by an at-home, non-invasive test that is now both guideline-preferred and reimbursed. Coverage and guideline status, not assay novelty, are what actually move screening rates.
Post angle: Two weeks apart: CMS covers a stool-RNA test, ACS names it preferred. 93% for cancer, 45% for advanced adenomas — non-invasive, at home, reimbursed for 65M people. The unglamorous option keeps winning on precancer. #CRC #GIOnc #Screening
#4
Source: International Journal of Cancer | Authors: Kahn CL, Therkildsen C and colleagues (Hvidovre Hospital, Denmark) | Published: April 27, 2026
Score: 8/20 — Base 5 (International Journal of Cancer — not in the fixed prestige table) + systematic review (+2) + comparative biomarker / precision framing (+1) = 8. The value here is comparative rather than novel: it is the only item in this edition that puts the competing assays on one page.
This systematic review screened 454 studies and found 20 that actually evaluated blood-based ctDNA colorectal screening in asymptomatic populations — the only setting in which a screening claim means anything. Across them, the most comprehensive assays (Shield, ColonSecure, FMBT-CRC) reached 71–85% sensitivity for early-stage colorectal cancer at 88–90% specificity. Only one assay, Coloscape, showed what the authors considered adequate advanced-adenoma detection, at 59% sensitivity and 92% specificity. Their conclusion is blunt and worth quoting to anyone selling a blood test as a colonoscopy alternative: no ctDNA assay yet demonstrates sufficient combined advanced-adenoma and early-stage-cancer sensitivity to be considered screening-ready, and none has been shown superior to FIT. Set against the same week's FDA approval, this is the useful corrective — approval establishes that a test performs as labelled, not that it outperforms the cheap stool test it is implicitly competing with.
Post angle: 20 studies of blood-based ctDNA screening in asymptomatic people. Best early-stage sensitivity 71-85%. Only one assay had decent advanced-adenoma detection. None beat FIT. Approval is not superiority. #CRC #GIOnc #LiquidBiopsy
#5
Source: JCO Precision Oncology | Authors: Murano T, Nakamura Y and colleagues (National Cancer Center Hospital East and 8 Japanese institutions) | Published: July 1, 2026
Score: 7/20 — Base 5 (JCO Precision Oncology — JCO-family specialty journal, consistent with the August 9 edition) + prospective multicentre cohort (+1) + biomarker-guided / precision (+1) = 7.
COSMOS-CRC evaluated the Shield cfDNA assay prospectively in 451 patients across eight Japanese institutions, and the stage gradient is instructive: 87.9% overall sensitivity for colorectal cancer, but 71.2% for stage I versus 97.4% for stages II–IV, and 37.0% for advanced precancerous lesions. The pattern is the same one running through this entire edition — cfDNA detection scales with tumour burden, so performance is excellent where it matters least for prevention and weakest where it would matter most. The study also opens a second use case worth watching: in the 70 patients with T1 disease, the assay had 100% sensitivity for lymph node metastasis, with specificity of 38.7% against 11.3% for current guideline pathological criteria, which the authors model as cutting unnecessary radical surgery after endoscopic resection from 78.6% to 54.3%. That is a smaller and more tractable question than population screening, and possibly where blood-based cfDNA earns its keep first.
Post angle: Shield in a prospective cohort: 97.4% sensitivity in stage II-IV, 71.2% in stage I, 37.0% in precancer. cfDNA scales with tumour burden — best where prevention matters least. The T1 lymph node signal may be the better use case. #CRC #GIOnc
Additional Papers of Interest
-
ASCO 2026 (LBA100) — in 142,250 participants across three annual screening rounds, the combined stage III/IV primary endpoint was not met (IRR 1.03, 0.92–1.14, p=0.63). The secondary endpoint of stage IV alone fell 14% (IRR 0.86, 0.744–0.998), strengthening across rounds, with a 34.4% reduction in stage IV colorectal diagnoses in the incident rounds — an exploratory subgroup within a secondary endpoint, and it should be read as hypothesis-generating rather than as a positive screening trial.
-
Gastroenterology — from Mannucci and Goel, the same group behind yesterday's DENEB assay: a six-biomarker exosome and cell-free RNA panel tested in 542 people across four countries, reporting AUC 95.6% in independent testing, 91.6% overall sensitivity, 97.3% for stages I–III and 61.5% for premalignant lesions with high-grade dysplasia. Aimed squarely at the under-50 population that current guidelines do not screen. Print issue February 2026; e-published December 9, 2025.
-
Gastroenterology — Taiwan's national FIT programme, 3,929,387 people screened and 89,771 post-polypectomy individuals analysed: colorectal cancer incidence rose stepwise from 2.2 to 4.0 per 1,000 person-years across faecal haemoglobin strata, and using that concentration to set surveillance intervals could cut colonoscopy demand by 9.8% versus current US guidelines while preserving comparable cancer risk. Relevant to every programme worrying about where the colonoscopy capacity for a screening expansion will come from.
-
Gut — in the French national screening programme, no increased risk of colorectal cancer, advanced-stage cancer or advanced adenoma was seen for delays of up to 24 months between a positive FIT and colonoscopy, while a faecal haemoglobin concentration of 200 µg/g or above carried 8-fold, 11-fold and 2-fold higher risks respectively. The actionable inversion: the test result, not the calendar, should be what determines who gets scoped first.
Back to all digests